Page 2
-
Deep Dive // PharmaVoice 100
The 2024 PharmaVoice 100
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
-
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
-
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
-
As election day nears, Trump and Harris veer in different directions on pharma
The two presidential candidates have developed diverging policies related to healthcare and pharma.
-
Will a Medicare boost propel digital therapeutics to the mainstream?
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
-
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
-
PharmaVoice 100
2024 PharmaVoice 100s: Standout Leaders
Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.
-
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
-
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
-
As AI transforms drug development, biotechs might not need as much Big Pharma support
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
-
Q&A
‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
-
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
-
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
-
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help.
-
How Roche plans to fill a projected $8B sales gap
Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.
-
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
-
Q&A
California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
-
Top pharma and biotech conferences 2025
Mark your calendars for the most important industry conferences in 2025.
-
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
-
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
-
Q&A
Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
-
Fresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.
-
Q&A // First 90 Days
Want better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
-
Bluebird to lay off another 25% of workforce in latest restructuring
The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.
-
Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.